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Abstract 28 
Peritoneal dialysis (PD) is an essential daily life-saving treatment for end-stage renal failure. PD 29 
therapy is limited by peritoneal inflammation, which leads to peritoneal membrane failure as a result 30 
of progressive fibrosis. Peritoneal infections, with the concomitant acute inflammatory response and 31 
membrane fibrosis development, worsen PD patient outcomes. Patients who remain infection-free, 32 
however, also show evidence of inflammation-induced membrane damage and fibrosis, leading to PD 33 
cessation. In this case, uraemia, prolonged exposure to bio-incompatible PD solutions and surgical 34 
catheter insertion have been reported to induce sterile peritoneal inflammation and fibrosis as a result 35 
of cellular stress or tissue injury. Attempts to reduce inflammation (either infection-induced or sterile) 36 
and, thus, minimise fibrosis development in PD have been hampered because the immunological 37 
mechanisms underlying this PD-associated pathology remain to be fully defined. Toll-like receptors 38 
(TLRs) are central to mediating inflammatory responses by recognising a wide variety of 39 
microorganisms and endogenous components released following cellular stress or generated as a 40 
consequence of extracellular matrix degradation during tissue injury. Given the close link between 41 
inflammation and fibrosis, recent investigations have evaluated the role that TLRs play in infection-42 
induced and sterile peritoneal fibrosis development during PD. Here, we review the findings and 43 
discuss the potential of reducing peritoneal TLR activity by using a TLR inhibitor, soluble TLR2, as a 44 
therapeutic strategy to prevent PD-associated peritoneal fibrosis. 45 
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Introduction 62 
Peritoneal dialysis (PD), an essential therapy for end-stage kidney disease, depends on the integrity of 63 
the peritoneal membrane. Despite advantages over other dialysis techniques, PD failure due to 64 
peritoneal membrane damage remains the major limiting factor (Davies et al., 1999;Williams et al., 65 
2003;Cho et al., 2014). Damage is driven by local peritoneal inflammation, which results in structural 66 
alterations of the peritoneal membrane, typically fibrosis – thickening of the sub-mesothelial compact 67 
zone – and vascular damage. This leads to altered solute transport through the membrane and dialysis 68 
failure (Lambie et al., 2013;Fielding et al., 2014).  69 
Peritoneal infections and the concomitant inflammation resulting from the activity of pathogen-70 
associated molecular patterns (PAMPS) derived from microbial components, are believed to be 71 
responsible for 20%-40% of PD failure (Cho et al., 2014;Pajek et al., 2014). However, peritoneal 72 
inflammation and fibrosis are also observed in PD patients without defined infectious episodes 73 
(Tomino, 2012;Cho et al., 2014). In this case, uraemia, prolonged exposure to bio-incompatible PD 74 
fluids and surgical catheter insertion have all been reported to induce sterile peritoneal inflammation, 75 
fibrosis and membrane failure by promoting tissue damage and cellular stress. This leads to the release 76 
and/or generation of endogenous cellular components and matrix degradation products, acting as 77 
damage-associated molecular patterns (DAMPs). The DAMPs trigger pro-inflammatory and pro-78 
fibrotic responses (Anders and Schaefer, 2014) that result in local angiogenesis, vasculopathy, 79 
epithelial-to-mesenchymal transition in mesothelial cells and collagen deposition in the sub-80 
mesothelial compact zone (Flessner et al., 2007;Johnson et al., 2012;Tomino, 2012;Cho et al., 81 
2014;Strippoli et al., 2016).  82 
The immune mechanisms linking infection-induced or sterile inflammation with the onset, 83 
development and regulation of PD-associated peritoneal fibrosis are poorly defined and thus the focus 84 
of intense investigation (Fielding et al., 2014;Liappas et al., 2015;Liappas et al., 2016;Raby et al., 85 
2018). Consequently, effective therapies to prevent PD-associated fibrosis remain to be developed. 86 
Critical to triggering pro-inflammatory responses is the activity of the Toll-like family of innate 87 
immune receptors (TLRs) (Kawai and Akira, 2010;Kawasaki and Kawai, 2014). TLRs are expressed 88 
in a variety of cell types, including peritoneal leukocytes and mesothelial cells (Colmont et al., 89 
2011;Raby et al., 2017). They recognise a wide range of microorganisms and their PAMPs (e.g., 90 
lipopolysaccharide/endotoxin/LPS; lipopeptides) as well as DAMPs released as a consequence of 91 
cellular stress (e.g., High Mobility Group Box-1 [HMGB-1]; heat shock proteins [Hsp]), or generated 92 
following extracellullar matrix degradation during tissue damage (e.g., hyaluronan, fibronectin) (Chen 93 
and Nuñez, 2010; Anders and Schaefer, 2014). TLR triggering results in the production of potent pro-94 
inflammatory and fibrotic mediators, e.g. IL-6, TGF-β, TNF-α, IL-8, IFN-γ, IL-1β (Fielding et al., 95 
2014;Kawasaki and Kawai, 2014). 96 
Inappropriate TLR activation may result in serious inflammatory conditions, therefore, they are being  97 
considered as therapeutic targets for the prevention and/or treatment of a number of inflammatory 98 
pathologies (Riedemann et al., 2003;Kanzler et al., 2007;Mollnes et al., 2008;Dunne et al., 2011;Raby 99 
et al., 2013). Given the close link between inflammation and fibrosis, and the recognised involvement 100 
of TLRs in tissue fibrosis (Anders and Schaefer, 2014), we recently assessed the role that TLRs play 101 
in peritoneal fibrosis development during PD (Raby et al., 2017;Raby et al., 2018). Here, we review 102 
the findings and discuss the potential of reducing peritoneal TLR activity by using the soluble form of 103 
TLR2, a TLR modulator, as a therapeutic strategy to prevent PD-associated peritoneal fibrosis. 104 
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Critical Contribution of TLR2 and TLR4 to PD-Associated Peritoneal Macrophage and 105 
Mesothelial Cell Pro-Inflammatory and Fibrotic Responses  106 
TLR2- and TLR4-mediated Peritoneal Macrophage and Mesothelial Cell Responses to 107 
Infection 108 
Recent studies have focused on TLR2 and TLR4, as these TLRs recognise the widest range of 109 
microbial components involved in PD-associated infections and are also the main TLRs involved in 110 
sterile inflammatory responses (Anders and Schaefer, 2014;Kawasaki and Kawai, 2014).  111 
Consistent with their expression detected in PD effluent (PDE)-isolated uremic leukocytes, TLR2 and 112 
TLR4 were found to mediate pro-inflammatory (IL-6, IL-8, TNF-α) and fibrotic (TGF-β, IL-6, IL-13, 113 
MMP1, MMP3, MMP9, TIMP-1) responses in PDE leukocytes stimulated with the Gram-positive 114 
bacterium Staphylococcus epidermidis, Pam3-Cys-Ser-(Lys)4 (Pam3Cys, a synthetic bacterial 115 
lipopeptide) – both TLR2 agonists – the Gram-negative bacterium Escherichia coli and the Gram-116 
negative bacterial cell-wall component LPS – both TLR4 agonists. Macrophages were the main cell 117 
type responsible for the observed leukocyte responses, consistent with their high TLR receptor 118 
expression compared with lymphocytes (Raby et al., 2017).  119 
Similar to peritoneal leukocytes, human peritoneal mesothelial cells (HPMC, from greater omentum) 120 
were found to respond to Pam3Cys, S. epidermidis and E. coli, but not to LPS. HPMC’s lack of response 121 
to LPS reflected the documented lack of TLR4 expression in HPMC (Colmont et al., 2011). However, 122 
HPMC responded to E. coli, most likely by recognising bacterial lipopeptides through TLR2 and 123 
flagellin – the protein component of the flagellum of Gram-negative bacteria – through TLR5 124 
expressed in these cells (Colmont et al., 2011).  125 
In vivo studies confirmed the critical role that TLR2 and TLR4 play in infection-induced peritoneal 126 
inflammation and fibrosis (Raby et al., 2017). A mouse model of peritoneal inflammation and fibrosis 127 
induced by repeated intraperitoneal injections of S. epidermidis (TLR2 agonist) or E. coli (TLR4 128 
agonist) was used. This model mimics the typical clinical episodes of recurrent bacterial peritonitis 129 
leading to peritoneal fibrosis observed in PD patients (Fielding et al., 2014). Repeated injection of S. 130 
epidermidis in wild-type (WT) mice resulted in substantial peritoneal fibrosis, whereas S. epidermidis 131 
injection in TLR2-deficient mice did not result in fibrosis development (Figure 1A). By contrast, 132 
injection of E. coli in TLR4-deficient mice resulted in a partial reduction in fibrosis when compared 133 
with WT mice (Figure 1B). This is consistent with the possibility that E. coli-induced pro-fibrotic 134 
responses may involve other receptors (e.g. TLR2, TLR5) in addition to TLR4. Together, these 135 
findings indicated a major role for TLR2 and to a lesser extent for TLR4 in bacteria-induced peritoneal 136 
fibrosis associated with PD, and pointed at controlling infection-induced TLR-mediated activation as 137 
a potential therapeutic against peritoneal fibrosis. 138 
TLR2- and TLR4-mediated Peritoneal Macrophage and Mesothelial Cell Responses to PD 139 
solutions   140 
The role of TLR2 and TLR4 in sterile inflammatory and fibrotic responses of peritoneal cells resulting 141 
from exposure to PD solutions (PDS) was also evaluated (Raby et al., 2018). A number of PDS elicited 142 
pro-inflammatory and pro-fibrotic responses (CXCL-8/IL-8, IL-6, TNF-α, TGF-β and IL-1β) from 143 
PDE-isolated uremic peritoneal leukocytes and mesothelial cells (from greater omentum), including 144 
those glucose-based (1.36% and 2.27% glucose Dianeal®, Physioneal®, Stay Safe®) or icodextrin-145 
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based (Extraneal®), having low pH (Dianeal®, Extraneal®, Stay Safe®) or physiologic pH 146 
(Physioneal®).   147 
Interestingly, analysis of the expression of inflammatory and immunity-related genes in uremic 148 
peritoneal leukocytes and HPMC exposed for 16h to low glucose Dianeal® (1.36% glucose), a 149 
commonly used PDS, showed substantial  modulation of a number of genes. In leukocytes, 15 genes 150 
were found significantly up-regulated by Dianeal®, and only 5 were down-modulated. The transcripts 151 
up-modulated by PDS included those coding for inflammatory mediators (CXCL8/IL-8, TNF-α, IFN-152 
γ, monocyte chemoattractant CCL2/MCP-1, the chemokine receptor CCR4, IL-1β) as well as for 153 
TLR2, TLR1, TLR6 (TLR2 signaling partners), TLR3, and TLR signal intermediates.   154 
In HPMC, 8 genes were found up-regulated and 6 down-regulated following exposure to Dianeal®. 155 
The transcripts for the pro-inflammatory cytokines IL-1α, IL-1β and CXCL8/IL-8 were strongly up-156 
modulated, whereas that for CXCL10/IL-10 – an anti-inflammatory cytokine – was found down-157 
modulated. Fibrosis-related gene expression analysis in Dianeal®-exposed HPMC – the cell type that 158 
contributes to peritoneal fibrosis by acquiring a fibroblastic phenotype following epithelial-to-159 
mesenchymal transdifferentiation (EMT) – showed a 3-fold increase in VGEFA (main isoform of 160 
VGEF) expression and a reduction in E-cadherin, both effects indicating EMT (Yung and Chan, 161 
2012;Ruiz-Carpio et al., 2017). 162 
Notably, peritoneal leukocyte TLR2 or TLR4 blocking with specific monoclonal antibodies inhibited 163 
the pro-inflammatory cytokine release induced by Dianeal®, and the extent of the inhibition depended 164 
on the PD patient tested. Simultaneous blocking of TLR2 and TLR4 resulted in a stronger inhibition 165 
of a number of pro-inflammatory and fibrotic cytokines released by the PDS-exposed uremic peritoneal 166 
leukocytes. TLR2 blockade in PDS-exposed HPMC also showed a significant reduction in pro-167 
inflammatory mediator release. Together, these findings indicated that peritoneal TLR2 and TLR4 168 
control inflammatory and fibrotic responses to PDS exposure. 169 
Interestingly, it was found that the cellular stress resulting from PDS exposure induces DAMP 170 
generation which in turn triggers TLR2 and TLR4 activation, and that the PDS does not contain pre-171 
existing components capable of TLR activation. Of note, Hsp70 and low (~33 kDa) and medium (~289 172 
kDa) molecular mass hyaluronan (HA) were identified as the main PDS-induced DAMPs. They elicited 173 
inflammatory responses from peritoneal cells through TLR2/TLR4 activation, as Hsp70 and HA are 174 
ligands of both TLR2 and TLR4 and their specific inhibition reduced PDS-induced inflammation in 175 
peritoneal leukocytes.  176 
It is worth noting that, in addition to eliciting inflammatory responses, heat-shock proteins have shown 177 
cytoprotective activity against cytotoxicity resulting from PDS exposure (Kratochwill et al., 2009). It 178 
is believed that peritoneal damage due to PD exposure may reflect an imbalance between cellular 179 
injury-induced inflammation and cytoprotective processes. The extracellular exposure to otherwise 180 
intracellular cytoprotective molecules such as Hsp70, released as a consequence of tissue damage/cell 181 
death, may trigger DAMP signals leading to pro-inflammatory responses and exacerbating peritoneal 182 
damage (Kratochwill et al., 2011)  183 
These findings suggested that inhibiting DAMP-TLR associations may have therapeutic potential 184 
against peritoneal fibrosis induced by PDS exposure. 185 
 186 
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Therapeutic Potential of Soluble TLR2 Against Infection-Induced and Sterile Peritoneal 187 
Inflammation and Fibrosis Associated with PD 188 
The therapeutic potential of inhibiting infection- or PDS-induced TLR activation to prevent peritoneal 189 
fibrosis development was evaluated by testing the ability of soluble Toll-like receptor 2 (sTLR2), a 190 
TLR inhibitor, to regulate peritoneal inflammation. It is well documented that sTLR2 reduces TLR-191 
mediated inflammation by both acting as a decoy receptor, binding to TLR2 ligands, and by interfering 192 
with the co-receptor activity of CD14, the main co-receptor for most TLRs (LeBouder et al., 2003;Raby 193 
et al., 2009;Raby et al., 2013).  194 
Inhibitory Effect of sTLR2 on PD-Associated Peritoneal Infection-Induced Inflammation and 195 
Fibrosis 196 
When administered together with the repeated peritoneal injection of S. epidermidis in mice, sTLR2, 197 
was found to prevent fibrosis development (Figure 2A) (Raby et al., 2017). This effect was 198 
accompanied by a substantial reduction of inflammatory parameters, including the peritoneal levels of 199 
a number of pro-inflammatory cytokines and chemokines, neutrophils (PMN) and monocytes at the 200 
peak time of their influx to the peritoneum as well as the prototypical pro-fibrotic cytokine TGF-β. Of 201 
note, in spite of reducing inflammation and phagocyte recruitment, the capacity of the mice to clear 202 
the infection was not found affected by the  presence of sTLR2, as no difference in bacterial load 203 
(peritoneum and blood) between mice treated and non-treated with sTLR2 was observed. 204 
Fibrosis-related gene transcripts were also markedly inhibited by sTLR2 administration. Of the 85 205 
genes tested, 21 were found markedly up-regulated by S. epidermidis, and sTLR2 reduced this effect 206 
in 18 of them. The transcripts reduced by sTLR2 included Fasl, central to apoptosis, which impairs 207 
bacterial clearance during PD (Hohlbaum et al., 2001;Catalan et al., 2003);   STAT-1, a critical signal 208 
intermediate for fibrosis development (Fielding et al., 2014), and IL-6 – a major promoter of peritoneal 209 
fibrosis (Fielding et al., 2014). Notably, sTLR2 counteracted S. epidermidis’ negative effect on matrix 210 
metalloproteinases (MMPs) Mmp-1, Mmp-3 and Mmp-9, and S. epidermidis’ positive effect on Mmp-211 
13 and the MMP inhibitor Timp-1 (Raby et al., 2017).  212 
Of note, peritoneal fibrosis induced by Gram-negative bacteria was also inhibited by sTLR2, as 213 
simultaneous peritoneal inoculation of sTLR2 with the repeated injection of E. coli resulted in reduced 214 
peritoneal fibrosis (Figure 2B). This reflects the fact that, in spite of not acting as a TLR decoy receptor 215 
for most Gram-negative bacterial components, sTLR2 can still reduce TLR-mediated fibrotic signaling 216 
induced by Gram-negative bacteria by inhibiting CD14, a co-receptor for most TLRs (Raby et al., 217 
2009), including TLR4. Thus, peritoneal fibrosis resulting from repeated peritoneal bacterial infections 218 
like those associated with PD can be inhibited by sTLR2 by acting on a variety of pro-inflammatory 219 
and fibrotic mediators, but notably, without affecting infection clearance. 220 
Inhibitory Effect of sTLR2 on PDS-Induced Peritoneal Inflammation and Fibrosis 221 
The therapeutic potential of sTLR2 against inflammation and fibrosis development resulting from 222 
prolonged peritoneal exposure to PDS was tested in a murine model of sterile peritoneal fibrosis 223 
consisting of daily peritoneal catheter infusions of a standard PDS (Raby et al., 2018). This mouse 224 
model mimics the changes in the peritoneal membrane (morphological and functional) observed in 225 
non-infected patients on PD (Gonzalez-Mateo et al., 2009;Loureiro et al., 2011). The peritoneal 226 
administration of sTLR2 together with the PDS twice weekly prevented the development of peritoneal 227 
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fibrosis (Figure 2C). In agreement with this finding, sTLR2 was found to suppress the PDS-induced 228 
increased expression of inflammatory and fibrotic mediators (TNF-α, IL-1β, KC, IL-6, IFN-γ). The 229 
suppressive effect of sTLR2 on inflammatory mediators correlated with a substantial reduction in the 230 
number of peritoneal leukocytes and the percentage of infiltrating neutrophils in particular (Raby et 231 
al., 2018). Notably, sTLR2 counteracted the negative effect of PDS on regulatory T cell (Treg) 232 
numbers, recovering their numbers to the levels observed following PBS inoculation. Tregs, an anti-233 
inflammatory T cell subset, control T cell expansion, including that of Th17 cells, an inflammatory T 234 
cell subset involved in peritoneal damage and fibrosis development (Liappas et al., 2016).  sTLR2’s 235 
positive effect on Treg cells resulted in an increased in the Treg:Th17 ratio. 236 
Analysis of fibrosis-related gene transcripts in mice peritoneal membranes carried out after the last 237 
inoculation of PDS+sTLR2 showed that sTLR2 also counteracted the positive effect of PDS on mRNA 238 
coding for several inflammatory mediators and fibrosis markers (Figure 2D).  Of the 85 genes tested, 239 
29 were markedly up-regulated by PDS at this time point, and sTLR2 was found to reduce this effect 240 
in 27 of them, including in the transcripts for FasL, STAT-1, IFN-γ, MMPs, TIMP1/3, TGF-β, IL-1β 241 
and TNF-α. Thus, the development of peritoneal fibrosis by long exposure to PDS can be prevented 242 
by administering sTLR2, which inhibits pro-inflammatory and fibrotic mediator production and 243 
controls the expansion of inflammatory cells. 244 
Conclusions 245 
The results of recent investigations reviewed here revealed the critical role that peritoneal TLR2 and 246 
TLR4, main members of the Toll-like family of innate immune receptors, play in mediating 247 
inflammation and fibrosis induced either by recurrent peritoneal infections during PD or prolonged 248 
exposure to PD solutions. Furthermore, the investigations showed the potential of a novel therapeutic 249 
strategy that targets TLRs to blunt peritoneal inflammation and thus prevent fibrosis development 250 
(either infection-induced or sterile) during PD by the use of a decoy receptor, sTLR2. This soluble 251 
receptor also inhibits the activity of CD14, the common TLR co-receptor. Thus, sTLR2 can reduce 252 
pro-inflammatory and fibrotic responses to different pathogens (e.g., Gram-positive and Gram-253 
negative bacteria) and their PAMPs and to endogenous TLR ligands (DAMPs) activating different 254 
TLRs, not only TLR2. These findings pave the way for future clinical trials to test the clinical efficacy 255 
of sTLR2 as a therapy for patients in long-term PD.  256 
Notably, the preclinical studies showed that peritoneal inflammation and fibrosis induced by bacteria 257 
in mice can be inhibited by sTLR2 without affecting the animal’s capacity to resolve the infection. 258 
Given that PD patients are prone to infections, this ability of sTLR2 would be advantageous when 259 
comparing with complete TLR blockade-based therapies e.g., by combination of anti-TLR2 and -TLR4 260 
antibodies (Lima et al., 2015), as these may have a detrimental effect on infection clearance. However, 261 
preclinical studies have shown the potential of combining anti-TLR2 and TLR4 antibodies with 262 
antibiotics to reduce inflammation whilst controlling infection (Spiller et al., 2008;Lima et al., 2015). 263 
Thus, a comparative evaluation of the efficacy of both TLR-targeting therapeutic strategies in PD 264 
models of infection/fibrosis will be required. Similarly, the efficacy of sTLR2 as a treatment for 265 
established fibrosis and membrane failure remains to be evaluated, since in the reported studies sTLR2 266 
was inoculated together with the infecting bacteria or the PD solution in an initially healthy peritoneal 267 
membrane. 268 
The pro-fibrotic cytokine TGF-β has been a main target for therapeutic interventions. Inhibition of its 269 
synthesis or activity showed promising effects (Duman et al., 2001;Margetts et al., 2002;Kyuden et al., 270 
2005;Loureiro et al., 2011;Tomino, 2012;Zhang et al., 2014;Nongnuch et al., 2015). However, given 271 
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TGF-β pleiotropic functions, its blockade is potentially hazardous (Blobe et al., 2000;Yoshimura et al., 272 
2010), and it is just one of several mediators of fibrosis acting down-stream of TLR activation. 273 
Thus, the reported sTLR2-based anti-fibrotic strategy may be a valuable complement to antibiotic 274 
therapies during PD infections, to biocompatible PDS or to PDS supplemented with 275 
immunomodulatory dipeptides to mitigate the PDS’ adverse effects (Ferrantelli et al., 2016). sTLR2 276 
may also be useful in other inflammatory conditions associated with PD, for example to help reduce 277 
the increased risk of cardiovascular diseases. 278 
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Figure Legends 443 
Figure 1. Critical contribution of TLR2 and TLR4 to bacteria-induced peritoneal fibrosis development.  444 
(A and B) Wild-type (WT), TLR2 deficient (TLR2-/-) or TLR4-/- mice (n=5 per group) were inoculated 445 
intraperitoneally 4 times at weekly intervals with S. epidermidis (S. epi., 5 x 108 CFU/mouse) or 446 
Escherichia coli (E. coli, 2 x 107 CFU/mouse) or left untreated (control). Four weeks after the last 447 
injection, histological analysis of the peritoneal membrane was conducted and the thickness of the sub-448 
mesothelial compact zone (SMC, layer between the muscle and membrane surface) was determined. 449 
Bar plots show the mean (± SEM) of SMC thickness in each experimental group. *, P<0.05; ***, 450 
P<0.005. (Adapted with permission from Raby et al., J Am Soc Nephrol. 2017. doi: 451 
10.1681/ASN.2015080923) 452 
 453 
Figure 2. Therapeutic potential of sTLR2 against bacteria- and PD solution-induced peritoneal fibrosis 454 
development. (A and B)  mice (n=5 per group) were inoculated intraperitoneally 4 times at weekly 455 
intervals with S. epidermidis (S. epi., 5 x 108 CFU/mouse) or Escherichia coli (E. coli, 2 x 107 456 
CFU/mouse) in the presence or absence of sTLR2 (250 ng/mouse), or left untreated (control). Four 457 
weeks after the last injection, histological analysis of the peritoneal membrane was conducted and the 458 
thickness of the sub-mesothelial compact zone (SMC) was determined. Bar plots show the mean (± 459 
SEM) of SMC thickness in each experimental group. *, P<0.05; ***, P<0.005. (C and D) Mice were 460 
instilled twice daily with 2 ml of PBS (n=5) or Fresenius Standard glucose solution (PDS, n=8) in the 461 
presence or absence of sTLR2 for 40 days before sacrifice, tissue sample collection and histological 462 
analysis of the peritoneal membrane for SMC thickness determination. Results show the mean (± SEM) 463 
for each experimental group. *P<0.05; **P<0.01.  Scatter plots in (D) show the effect of PDS on the 464 
expression of fibrosis-related genes in the absence and presence of sTLR2, as assessed by quantitative 465 
RT-PCR on RNA extracted from peritoneal membrane samples. Dotted lines indicate the 0.5 and 2 fold 466 
change thresholds. Open circles outside the dotted lines correspond to genes modulated in a non-467 
statistically significant manner. (Adapted with permission from Raby et al., Kidney Int. 2018. 468 
doi.org/10.1016/j.kint.2018.03.014) 469 
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